San Francisco, United States
Glycyx, a highly innovative biotech firm founded in 2020 and headquartered in the United States, is tackling a critical yet often overlooked challenge in cancer treatment—opioid-induced immunodeficiency that diminishes the efficacy of immunotherapy. Known as Opioid-Induced Immunotherapy Failure (OIIF), this condition is addressed through Glycyx's pioneering approach.
With their slogan, "Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance immunotherapy efficacy," Glycyx is positioned at the intersection of biopharma, biotechnology, and pharmaceutical industries. Their novel small molecule, axelopran, is developed to counteract opioids’ immunosuppressive effects without sacrificing pain relief. It is designed to bolster immune checkpoint inhibitor (ICI) therapies as a combination solution, enhancing cancer treatment options.
This promising therapy is now Phase 2 ready with established safety credentials and demonstrated preclinical efficacy. Following a successful $3.50M Series A investment as of 01 July 2023, Glycyx is strategically positioned to revolutionize cancer treatment paradigms and greatly improve both survival rates and quality of life for cancer patients worldwide.
